Core Viewpoint - Xianle Health has received approval from the Thailand Board of Investment for establishing a production base in Thailand, focusing on modern technology food production and processing [1] Investment Approval - The Thailand Board of Investment approved Xianle Health's application for investment, allowing the company to engage in food and beverage production, food additives, food ingredients, and dietary supplements manufacturing [1] - The approval includes the use of agricultural by-products or waste as raw materials for production activities, along with corresponding rights and incentives [1] Board Meeting and Funding - On November 28, 2024, the company held its fourth board meeting, where it approved the proposal for establishing a production base in Thailand [1] - The board agreed to use self-owned and self-raised funds totaling no more than $40 million for the investment [1] - The investment will be executed through Xianle Holdings Limited, a wholly-owned subsidiary in Hong Kong, and Xianle Holdings (Asia) Limited, a wholly-owned subsidiary in Singapore, to establish a wholly-owned project company, Xianle Health Technology (Thailand) Co., Ltd. [1]

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-052 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 1 公司将继续积极推进本次对外投资相关工作，并按照相关法律法规的规定及 时披露进展情况，敬请广大投资者注意投资风险。 四、备查文件 1、泰国投资促进委员会办公室出具的批准信。 仙乐健康科技股份有限公司 关于在泰国投资建设生产基地进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本次对外投资概述 仙乐健康科技股份有限公司（以下简称"公司"）于 2024 年 11 月 28 日召 开第四届董事会第四次会议，审议通过了《关于在泰国投资建设生产基地的议案》， 董事会同意公司使用自有资金和自筹资金合计不超过 4000 万美元，通过公司的 香港全资子公司仙乐控股有限公司和新加坡全资孙公司仙乐控股（亚洲）有限公 司在泰国合资设立全资项目公司仙乐健康科技（泰国）有限公司（暂定名，以泰 国公司注册机关核准的名称为准）投资建设泰国生产基地，并同意授权公司管理 层及其授权人员采取必要 ...

Core Viewpoint - The current Chinese nutrition and health food market is undergoing significant transformation, with new consumption trends creating opportunities for growth, particularly for leading B-end enterprises [1] New Channels - Four core growth directions identified: interest e-commerce and grass-planting communities, online cross-border sales, private domain e-commerce, and new retail offline. a) Douyin-driven interest e-commerce and Xiaohongshu-based grass-planting communities are thriving, with Douyin's health product sales expected to grow by 52.5% year-on-year in 2024; b) Online cross-border health products are experiencing explosive growth, with Douyin's global purchase GMV projected to increase by 204% year-on-year in 2024; c) Private domain e-commerce is characterized by high average order value and strong repurchase rates, expected to develop rapidly; d) Offline new retail supermarkets are in the process of expanding, with significant growth anticipated in health product sales [2] New Trends - The diversification of efficacy and the emergence of snack-like dosage forms are raising demands on supply-side R&D capabilities. The "self-care economy" is flourishing, leading consumers to have more specific and personalized efficacy expectations; emerging dosage forms like gummies and beverages offer palatability and convenience, fostering daily consumption habits [3] All-Age Groups - The consumer base for health products is becoming increasingly age-diverse. Young consumers are emerging as a new force in health product consumption due to the popularization of health and wellness concepts and work-related stress. Initially dominated by the "her economy," focusing on oral beauty, weight management, and women's health, the market is now seeing active participation from the "his economy," with manufacturers focusing on liver protection and fatigue resistance [4] Advantages of Leading B-End Enterprises - As new consumer brands in the nutrition and health food industry rise, C-end sales are expected to grow at a mid-to-high single-digit CAGR. The market for dietary supplements in China is projected to reach 232.34 billion yuan in 2024, with a year-on-year growth of 3.7%. Despite a slowdown due to a high base in 2023 and significant declines in pharmacy channels, the long-term growth trend remains intact. The per capita consumption of nutrition and health products in China is significantly lower than in mature markets like the US, Japan, and Australia, indicating potential for growth. The "Healthy China" strategy, stable economic development, and the expansion of the consumer base across all age groups are expected to drive continued growth in the C-end market. Enterprises with stronger R&D capabilities and scale advantages are likely to capture higher market shares, with the B-end market further concentrating towards leading players [5]

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-050 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 特别提示： 1、仙乐健康科技股份有限公司（以下简称"公司"）2024 年度权益分派方 案已获 2025 年 5 月 8 日召开的 2024 年年度股东大会审议通过。 2、公司回购专用证券账户中的股份不享有利润分配及资本公积金转增股本 的权利，因此，公司回购专用证券账户中的回购股份 1,285,600 股不参与本次权 益分派。本次权益分派方案为以公司总股本 237,274,117 股扣除回购专用证券账 户股份 1,285,600 股后的股本 235,988,517 股为基数，向全体股东每 10 股派发现 金红利 6.50 元（含税），合计派发现金红利 153,392,536.05 元（含税），同时进行 资本公积金转增股本，全体股东每 10 股转增 3 股，合计转增股数 70,796,555 股。 转增后公司总股本将增加至 308,070,672 股。本次不送红股，剩余未分配利润结 转至下一年度。 3、 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-051 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于调整仙乐转债转股价格的公告 债券代码：123113 转股价格调整起始日期：2025 年 5 月 27 日 一、转股价格调整依据 根据仙乐健康科技股份有限公司（以下简称"公司"）《创业板向不特定对 象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）发行条款 及中国证监会关于可转换公司债券发行的有关规定，仙乐转债发行之后，若公司 发生转增股本、派送现金股利情况，则转股价格相应调整。具体的转股价格调整 公式如下： 转增股本：P1=P0/（1+n）； 派送现金股利：P1=P0-D； 1 上述两项同时进行：P1＝（P0-D）/（1+n）。 债券简称：仙乐转债 调整前转股价格：人民币 41.96 元/股 调整后转股价格：人民币 31.82 元/股 2 个归属期归属条件成就的议案》、《关于 ...

方正证券主要观点如下： 2)新趋势：功效多元化、剂型零食化，对供给端的研发能力提出更高的要求。功效方面，当前"悦己经 济"蓬勃发展，消费者对功效的期待变得更加具体且个性化，比如单个产品开发复合功效，这要求供给 端具备市场洞察捕捉各类群体的隐蔽健康痛点，同时也要具备开发循证有效产品的研发能力;剂型方 面，软糖、饮品等新兴剂型兼具适口性与便利性，有利于培养消费者的日常服用习惯，根据灼识咨询， 22-24年软糖/饮品剂型CAGR分别约为40%/30%，剂型增速领先，这要求供给端具有充足的新剂型产能 及出色的研发能力。 方正证券发布研报称，当前中国营养保健食品市场处于重要变革期，新消费驱动下行业呈现渠道多元 化、产品创新化、人群全龄化三大特征。该行重视积极把握新消费变革趋势的头部B端企业，新消费驱 动业绩增长，或有望带来板块的估值切换。建议关注积极布局新消费赛道的头部企业，推荐聚焦高价值 客户拓展的仙乐健康（300791）(300791.SZ)及布局跨境与宠物营养的百合股份（603102） (603102.SH)。该行预计，未来行业将保持中高个位数复合增长，头部企业集中度有望加速提升。 当前中国营养保健食品市场处于重 ...

Summary of Conference Call Records Industry Overview: Health Supplements - The health supplement industry is experiencing structural growth, with a compound annual growth rate (CAGR) of 5% from 2017 to 2022, indicating mid-to-low growth but emerging opportunities under new consumption trends [1][2] - The market size for health supplements is approximately over 1 trillion yuan, with significant potential for growth as new consumption companies enter the sector [2] Key Companies and Their Performance Xianle Health - Xianle Health has successfully transformed from an OEM to a new consumption company, achieving profitability and valuation improvement since 2022 by divesting loss-making businesses [1][5][36] Yanjichu - Yanjichu, a leading OEM in bird's nest products, has a competitive edge with 2,000 clients and 70 patents. If it can penetrate the consumer market, its valuation could rise significantly from below 15 times to over 20 times [1][11][12] Yanjinpuzi - Yanjinpuzi has shown strong market performance since 2021, benefiting from bulk retail channels. Despite short-term profit margin declines, long-term growth potential remains promising [1][3][4] HH International Holdings - HH International focuses on adult health products and is benefiting from online transformation. The company is upgrading its brand matrix and reducing debt to optimize interest expenses [3][29] Tongchen Beijian - Tongchen Beijian has become a market leader in health supplements since 2019, with a stable market share of nearly 10%. The company is focusing on new product launches and online sales channels [26][35] Baihe Health - Baihe Health is expanding into new channels, particularly membership supermarkets, which are expected to double its scale this year [37] Market Trends and Dynamics - The global health supplement market is growing steadily, with China's growth rate surpassing the global average, driven by aging populations and new consumption trends [3][20][22] - The online transformation of health brands is accelerating, with e-commerce channels gaining a significant share of the market [25][27] - The health supplement industry is characterized by high gross margins, primarily due to strong brand attributes and a fragmented supply chain [14][15][16] Investment Opportunities and Risks - The health supplement sector presents substantial investment opportunities, akin to blue-chip stocks from a few years ago, with new brands needing to embrace new consumption paths [9][10] - The industry is witnessing a shift towards light asset models, with increasing product homogeneity and a fragmented brand landscape [28] - The aging population in China is a fundamental driver for the health supplement market, as older consumers have a consistent demand for health products [23][24] Conclusion - The health supplement industry is poised for growth, with several companies demonstrating strong performance and potential for further expansion. Investors are encouraged to consider the emerging opportunities within this sector, particularly as new consumption trends reshape the market landscape [1][9][24]

Investment Rating - The report maintains an "Accumulate" rating for the company, indicating a projected increase of 5% to 15% relative to the CSI 300 index over the next six months [10]. Core Views - The company has shown significant growth in overseas markets, with a notable shift in revenue distribution towards international sales, which now account for 60.56% of total revenue, up from 39.44% the previous year [5][6]. - In 2024, the company achieved a revenue of 42.11 billion yuan, a year-on-year increase of 17.56%, and a net profit of 3.28 billion yuan, reflecting a growth of 16.70% [5]. - The company's main products, soft capsules and gummies, contributed over 70% of total revenue, with soft capsules generating 19.84 billion yuan (up 29.91%) and gummies 9.95 billion yuan (up 34.54%) in 2024 [5][6]. - The gross profit margin for the main business improved to 31.05%, with the gross margin for soft capsules slightly decreasing to 25.57% and for gummies increasing to 48.88% [5][6]. Summary by Sections Financial Performance - In Q1 2025, the company reported a revenue of 9.54 billion yuan, a slight increase of 0.28% year-on-year, while the net profit was 0.65 billion yuan, up 0.21% [5]. - The domestic market faced challenges, leading to limited sales growth in Q4 2024 and Q1 2025, with revenue growth rates dropping significantly compared to previous periods [5]. - The company forecasts earnings per share (EPS) of 1.68 yuan, 2.08 yuan, and 2.41 yuan for 2025, 2026, and 2027 respectively, with corresponding price-to-earnings ratios of 16.01, 12.88, and 11.14 based on the closing price of 26.85 yuan on May 14 [6][7]. Market Dynamics - The Americas market saw a remarkable revenue growth of 59.56%, contributing 39.56% to the main revenue, while the European market grew by 14.25% [5][6]. - The report highlights that the company’s expansion strategy, including the acquisition of BF, positions it well in the U.S. market, which is expected to remain unaffected by new trade tariffs [6].

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

Group 1 - The pet economy concept rose by 1.98%, ranking third among concept sectors, with 54 stocks increasing in value, including major gainers like Meino Biological and Jieya Co., which hit the 20% limit up [1][2] - Notable stocks with significant increases include Xianle Health, Huisheng Biological, and Yiyuan Magic Yam, which rose by 13.41%, 10.50%, and 9.10% respectively [1] - The leading decliners in the sector were Zhiou Technology, Qingmu Technology, and Yingstone Network, which fell by 4.64%, 4.42%, and 2.73% respectively [1] Group 2 - The pet economy sector saw a net inflow of 236 million yuan, with 48 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top stock for net inflow was Yong'an Pharmaceutical, with a net inflow of 68.36 million yuan, followed by Jieya Co., Ruoyuchen, and Meino Biological with net inflows of 48.24 million yuan, 46.14 million yuan, and 45.47 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Jieya Co., Jiabiyou, and Meino Biological led with net inflow rates of 27.98%, 13.31%, and 11.04% respectively [3] - The pet economy sector's inflow ranking included stocks like Yong'an Pharmaceutical, Jieya Co., Ruoyuchen, and Meino Biological, all showing strong performance in terms of trading volume and turnover rates [3][4]